Scarica l'app Stockscreener
5.705
0.61%
-0.035
Precedente Chiudi:
$5.74
Aprire:
$5.72
Volume 24 ore:
1,712
Relative Volume:
0.04
Capitalizzazione di mercato:
$179.11M
Reddito:
$15.33M
Utile/perdita netta:
$-40.19M
Rapporto P/E:
-3.2559
EPS:
-1.7522
Flusso di cassa netto:
-
1 W Prestazione:
+2.79%
1M Prestazione:
+1.15%
6M Prestazione:
+34.24%
1 anno Prestazione:
-39.88%
Intervallo 1D:
$5.63
$5.81
Intervallo di 1 settimana:
$5.262
$5.81
Portata 52W:
$3.50
$10.24
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Nome
Trisalus Life Sciences Inc
Settore
Industria
Telefono
415 336 8917
Indirizzo
6272 WEST 91ST AVENUE, WESTMINSTER
Confronta TLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.72 | 179.11M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
129.19 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.67 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
337.62 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.42 | 105.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Lake Street | Buy |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Iniziato | ROTH MKM | Buy |
| 2024-10-25 | Iniziato | Northland Capital | Outperform |
| 2024-09-16 | Iniziato | Oppenheimer | Outperform |
| 2024-05-30 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Trisalus Life Sciences Inc Borsa (TLSI) Ultime notizie
TriSalus Life Sciences, Inc. SEC 10-K Report - TradingView
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? - Nasdaq
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday - Defense World
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates - MSN
TriSalus Life Sciences Reports Strong Growth Amid Challenges - MSN
Canaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks - Seeking Alpha
TriSalus Life Sciences’ (TLSI) “Buy” Rating Reiterated at Canaccord Genuity Group - The AM Reporter
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth - Investing.com India
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic - Asianet Newsable
Trisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetration - MSN
TriSalus Life Sciences Reports Strong 2024 Growth - TipRanks
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences Confirms Positive Outlook For FY25Update - Nasdaq
TriSalus Life Sciences Inc Reports Q4 Revenue of $8.3M, Exceedin - GuruFocus
TriSalus Life Sciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
TRISALUS LIFE SCIENCES Earnings Results: $TLSI Reports Quarterly Earnings - Nasdaq
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
Examining the Future: TriSalus Life Sciences's Earnings Outlook - Benzinga
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping - Marketscreener.com
Medicare Approves $11K+ Reimbursement for TriNav Cancer Treatment SystemMajor Win for Hospitals - Stock Titan
TRISALUS LIFE SCIENCES Earnings Preview: Recent $TLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System - Business Wire
TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday - Defense World
TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code - Business Wire
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 10.7% – Here’s What Happened - Defense World
Can This Revolutionary Liver Cancer Treatment Double Drug Effectiveness? New Study Shows Remarkable Results - StockTitan
Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3% - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts - Defense World
TriSalus Life Sciences announces executive departure By Investing.com - Investing.com South Africa
TriSalus Life Sciences announces executive departure - Investing.com India
3 Stocks With Robust Growth Outlooks Insiders Are Buying - MSN
Trisalus Life Sciences CFO buys $33,900 in common stock - MSN
Dated alert on Trisalus Life Sciences entering credit agreement withdrawn -February 19, 2025 at 08:04 am EST - Marketscreener.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Lake Street Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Lake Street Capital - Defense World
Lake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation - Nasdaq
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat
Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) versus Tenon Medical (NASDAQ:TNON) - Defense World
Trisalus Life Sciences Inc Azioni (TLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):